Skip to content

    Lung Cancer Health Center

    Font Size

    Pill Shrinks Some Lung Cancers

    Crizotinib Shows Promise for Lung Cancer Patients With ALK Genetic Abnormality
    WebMD Health News
    Reviewed by Laura J. Martin, MD

    June 7, 2010 (Chicago) -- An experimental pill shrank tumors in lung cancer patients who have a specific genetic abnormality.

    After treatment with the drug crizotinib, tumors shrank or stopped growing in more than 90% of 82 advanced lung cancer patients with the genetic abnormality. In 57%, tumors shrank by 30% or more. Side effects were generally mild.

    "That's huge for a population of lung cancer patients where most treatments have only a 10% response (tumor shrinkage) rate, with considerable toxicity," says Indiana University's George W. Sledge Jr., MD, incoming president of American Society of Clinical Oncology (ASCO).

    It’s too early to know if the drug actually extends lives. And only the 4% of lung cancer patients worldwide with the gene abnormality targeted by the drug are typically helped by crizotinib.

    Still, that translates to more than 8,000 people in the U.S. each year, Sledge tells WebMD.

    The findings were presented at ASCO's annual meeting.

    How Crizotinib Works in Lung Cancer

    Crizotinib blocks an aberrant protein called ALK that is critical for the growth and survival of cancer cells.

    In some people, an aberration causes the ALK gene to fuse with another gene, typically EML4 in lung cancer.

    This, in turn, inappropriately turns on the ALK gene so it produces more and more of the ALK protein, driving tumor growth.

    No one knows exactly why it happens, but lung cancer patients with the abnormality are generally nonsmokers. And they're typically younger, in their 50s on average. The abnormality is not inherited.

    It's easy to test for ALK aberration, "so we can tell right away if you’re likely to respond to the drug," says Roy Herbst, MD, chief of thoracic medical oncology at the University of Texas M.D. Anderson Cancer Center in Houston. He was not involved with the work.

    Only 28% Chance of Lung Cancer Progression

    People in the study had advanced non-small-cell lung cancer (NSCLC), the most common type of cancer. In many cases, the disease had already spread to other parts other body. They had failed to respond to an average of three, and up to seven, drugs.

    1 | 2 | 3

    Today on WebMD

    Xray analysis
    Do you know the myths from the facts?
    chest x-ray
    Get to know them.
    woman taking pills
    Tips to managing them.
    Lung cancer xray
    See it in pictures, plus read the facts.
    Lung Cancer Risks Myths and Facts
    Woman getting ct scan
    Improving Lung Cancer Survival Targeted Therapy
    cancer fighting foods
    Lung Cancer Surprising Differences Between Sexes
    Pets Improve Your Health
    Vitamin D
    Lung Cancer Surgery Options